Key opinion leaders and presenters at the ACTRIMS Forum 2022 share their perspectives on the latest data and updates in the management of patients with multiple sclerosis (MS).
February 11th 2022
Jeffrey Cohen, MD, director, Mellen Center for MS Treatment and Research, Cleveland Clinic; and president, ACTRIMS, discussed what he is looking forward to at the 2022 ACTRIMS Forum, as well as the overarching themes of the meeting. [WATCH TIME: 2 minutes]
March 8th 2022
Leigh Charvet, PhD, professor of neurology, NYU Grossman School of Medicine, discussed the potential feasibility of at-home tDCS for patients with multiple sclerosis to boost cognitive training. [WATCH TIME: 2 minutes]
March 9th 2022
The William S. and Lois Stiles Edgerly Professor of Neurology and Professor of Immunobiology, and Neurologist-in-Chief at Yale-New Haven Hospital spoke to the findings of a recent assessment of T cells in multiple sclerosis. [WATCH TIME: 4 minutes]
March 10th 2022
The staff neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis Treatment and Research offered her insight into improving the recognition of autoimmune encephalitis. [WATCH TIME: 2 minutes]
March 11th 2022
The assistant professor of neurology at the University of Pennsylvania discussed how 7T MRI features of newly developed MS lesions can predict the development of chronic active lesions. [WATCH TIME: 3 minutes]
Cognitive Functioning and Motor Difficulties Identified in Spinal Muscular Atrophy Type 3
Background Factors Drive Elevated Risk of Neonatal Seizures, Epilepsy in Children of Mothers on SSRI/SNRIs
Advocacy’s Part in the Progress in ALS: Matthew B. Harms, MD
This Week on NeurologyLive® — May 16, 2022